Biological Modeling Specialty Section

James V. Bruckner, Ph.D., President

Dr. Bruckner received his B.S. in pharmacy and M.S. in toxicology from the University of Texas, as well as Ph.D. in toxicology from the University of Michigan. He has held faculty positions at the University of Kansas, the University of Texas Medical School at Houston, and the University of Georgia (UGA). He is currently Professor of Pharmacology and Toxicology at UGA. He was the director of UGA’s Interdisciplinary Graduate Program in Toxicology for 15 years. Dr. Bruckner has served on a number of journal editorial boards. His areas of research include toxicokinetics, xenobiotic metabolism, physiologically-based pharmacokinetic (PBPK) modeling of solvents and pesticides, consequences of drug-solvent interactions to cancer risks of environmental exposure levels of solvents, and toxicokinetic bases for susceptibility of children to insecticides and other chemicals. Dr. Bruckner has published more than 200 journal articles, book chapters (e.g., Casarette and Doull) and abstracts. He has served on a variety of study sections, expert panels and committees for the U.S. EPA, NIEHS, NASA, Air Force, ACGIH, ATSDR/CDC, U.S. FDA, and NRC. He is currently a member of the NRC Committee on Toxicology. He has been a member of SOT since 1974, and has served on the SOT Education Committee and Committee on Regulatory Affairs and Legislative Assistance.

Biological Modeling Specialty Section

Cecilia Tan, M.S., M.B.A., Ph.D., Vice President-Elect

Dr. Tan is a Physical Research Scientist at the U.S. Environmental Protection Agency (U.S. EPA). She received her B.S. in Environmental Engineering from the National Cheng Kung University in Taiwan, M.S. in Environmental Health Sciences from Harvard School of Public Health, MBA from North Carolina State University, and Ph.D. in Environmental Science and Engineering from the University of North Carolina at Chapel Hill in 2001. She was a postdoctoral fellow at CIIT (now The Hamner Institutes for Health Sciences) from 2001–2004, and was the Associate Director of the Center for Human Health Assessment at CIIT from 2004–2009. Her research focus was application of pharmacokinetic and pharmacodynamic modeling in supporting human health risk assessment. In 2009, Dr. Tan joined the U.S. EPA where her research interests continued in computational modeling and risk assessment. She has been a member of the SOT since 2002 and has served in the following capacities: Biological Modeling Specialty Section/Councilor and Mixtures Specialty Section/Councilor.

Biotechnology Specialty Section

Hanan Ghantous, Ph.D., DABT, Vice President

Dr. Ghantous received a B.Sc. in Pharmacy from the University of Baghdad, Iraq, a M.Sc. in Pharmacology from the University of Strathclyde, Scotland and a Ph.D. in Toxicology from the University of Uppsala, Sweden. She was a postdoctoral fellow in the Department of Anesthesiology, Pharmacology/Toxicology Division, University of Arizona, and received her board certification as a Diplomate of the American Board of Toxicology (DABT) in 1995. In 2001, Dr. Ghantous joined the U.S. Food and Drug Administration, and since 2007 she has been the Pharmacology/Toxicology supervisor at the Division of Antiviral Products, Center for Drug Evaluation and Research. Since joining the U.S. FDA, she has evaluated pharmacology/toxicology data to support the safe clinical development of small molecule drugs and biological products. Dr. Ghantous has presented at national and international scientific and regulatory meetings, has served on several U.S. FDA committees, has been involved in writing Guidance documents and has represented the Agency at various public forums. Before U.S. FDA, Dr. Ghantous worked for approximately 10 years at the DuPont Company, as a Research Toxicologist at DuPont Haskell Laboratory, and Project Registration Manager—U.S. Regulatory Toxicologist at the Crop Protection Division. She has been a member of the Society of Toxicology since 1989 and the American College of Toxicology since 2000. She is serving as a member of the Continuing Education Committee of SOT (2010–2013), and as a councilor in the Biotechnology Specialty Section. She is also serving as a member of the Board of Directors of the American Board of Toxicology (2010–2014). Dr. Ghantous has over 20 years of combined experience in general and regulatory.

Biotechnology Specialty Section

Laura Andrews, Ph.D., DABT, Vice President-Elect

Dr. Andrews is Vice President of Pharmacology and Toxicology at Genzyme where she directs the nonclinical development programs for biotherapeutics. She is responsible for the nonclinical development programs for therapeutic biologics, gene therapy products, and cell based therapies. She oversees the design, implementation and interpretation of the in vivo GLP studies and the in vitro assays to support product development. Dr. Andrews has authored the pharmacology and toxicology section for several Genzyme INDs and marketing applications in several different territories. She received a B.S. (1983) in Biology and Chemistry from Dickinson College, and a Ph.D. (1987) in Pathology and Cell Biology from Thomas Jefferson University and Medical College in Philadelphia, PA. She was Board Certified in General Toxicology in 1998. Dr. Andrews holds memberships in the Society of Toxicology (SOT), Society for Toxicologic Pathology (STP) and the American College for Toxicology (ACT). She is Vice President-Elect for the Biotechnology specialty section within SOT. In addition, she is a member of SACATM (Scientific Advisory Committee on Alternative Toxicological Methods). She has just finished serving on the Board of Directors for the American Board of Toxicology and is a Fellow of the Academy of Toxicologic Sciences.

Biotechnology Specialty Section

Barbara Mounho, Ph.D., D.A.B.T., Past President

Barbara joined the toxicology department at Amgen Inc. (Thousand Oaks, CA) in 2002. Her work involves supporting the development of biopharmaceutical candidates for various therapeutic areas such as oncology and inflammation. She has expertise in the preclinical safety assessment of protein therapeutics including monoclonal antibodies, recombinant and fusion proteins, and antibody-drug conjugates. Barbara recently transitioned to Amgen’s Regulatory Biosimilar Group, and is involved in advancing advocacy efforts to establish a science-based pathway for U.S. biosimilars.

Prior to joining Amgen Inc., she was a toxicologist in the Safety Assessment Department at Genentech Inc. (South San Francisco, CA), and worked on the development of various drug candidates including small and large molecule drug products. Barbara is a diplomate of the American Board of Toxicology, and currently a member of various organizations including the American College of Toxicology (ACT), Society of Toxicology (SOT) and BioSafe. Barbara is actively involved in the toxicology field, and has served as a member of the ACT Council (2005–2008), the ACT Continuing Education Committee (2003–2005), and has served as the chair for the ACT Study Director Training Continuing Education Course for several years. She has also served as a member of the SOT Continuing Education Committee (2006–2009), the Continuing Education Committee Student Liaison (2008), and is currently the President of the SOT Biotechnology Specialty Section. She has authored several journal articles and book chapters, as well as presented at numerous meetings and conferences on challenges associated with the preclinical development of biotherapeutics.

Carcinogenesis Specialty Section

David E. Williams, Ph.D., President

Dr. Williams (Professor, Environmental and Molecular Toxicology, Senior Scientist, The Linus Pauling Institute, member Environmental Health Sciences Center and Director, Superfund Research Program at Oregon State University) received his B.S. from Reed College and Ph.D.in Biochemistry and Biophysics at Oregon State University (OSU). Following postdoctoral training in Biochemistry at The Medical College of Wisconsin, Dr. Williams returned to OSU and has been on the faculty for 23 years. Dr. Williams’ research area is drug metabolism, carcinogenesis and cancer chemoprevention. He serves as an Associate Editor for TAAP. In addition to the Carcinogenesis Specialty Section, he has served on the following SOT committees: Program (1991–1994); Education (1997–1999); K–12 Education (1997–1998, Chair,1998–1999); Food Safety Specialty Section (Secretary/Treasurer, 1998–2000); and PANWAT (Secretary/Treasurer, 1990–1992; President, 1996–1997). He was a member of AL-TX1 (Chair, 2 years) and is currently serving on XNDA. He has authored 165 manuscripts and is the 2009 OSU Alumni Distinguished Professor.

Carcinogenesis Specialty Section

Helmut Zarbl, Ph.D., ATS, Vice President

Dr. Zarbl is a Professor of Environmental and Occupational Medicine at Robert Wood Johnson Medical, UMDNJ, the Director of the NIEHS Center of Excellence at UMDNJ/Rutgers, and Associate Director of Public Health Science at the Cancer Institute of New Jersey. He received his doctorate in Biochemistry from McGill University in 1983. He was a postdoctoral fellow at NCI from 1983–1985, and at the Clinical Research Institute of Montreal from 1985–1987, where studied oncogenes and tumor suppressor genes in chemical carcinogenesis. In 1987, Dr. Zarbl became Assistant Professor at MIT, where his research interests continued to focus on carcinogenesis. In 1996, he joined the Fred Hutchinson Cancer Research Center where he performed research on genetic susceptibility, epigenetics, and toxicogenomics. He has served on numerous national and international Study Sections, Scientific Advisory Boards, Committees, Review Boards, and Editorial Boards. Dr. Zarbl has co-authored more than 70 peer-reviewed articles, review articles, book chapters, etc. He is currently on the “National Academy Standing Committee on Use of Emerging Science for Environmental Health Decisions.” He has been a member of the SOT since 2003 and has served the SOT in the following capacities: Founding Chair, Disease Prevention Task Force; Vice President, Carcinogenesis Specialty Section.

Carcinogenesis Specialty Section

Vernon E. Walker, D.V.M., Ph.D., Past President

Dr. Walker received his D.V.M. from The University of Tennessee in 1983 and a Ph.D. from Duke University in 1991. He was a pathology resident at the University of Alabama at Birmingham and Auburn University (1983–1985) and a postdoctoral fellow in pathology at the University of North Carolina (1991–1993). In 2009, Dr. Walker joined the Department of Pathology, University of Vermont. He has served as an ad hoc reviewer for the NIH, U.S. FDA, and NIOSH, and reviewed grants for the American Chemistry Council and the Health Effects Institute (1994–Present). He has served on numerous advisory committees for U.S. and Canadian agencies, foundations, and industry. He has been a member of the SOT since 1997, served as a councilor in the Carcinogenesis Specialty Section (2008–Present), and has been active in the student awards program of that specialty section. His research interests are in chemical carcinogenesis, in particular low-dose effects of mutagens.

Cardiovascular Specialty Section

Matthew Campen, Ph.D., M.S.P.H., President

Dr. Campen received his B.S. from Virginia Polytechnic Institute in 1994, and his M.S.P.H. and Ph.D. in Environmental Health from the University of North Carolina at Chapel Hill in 1997 and 2000, respectively. He completed his postdoctoral training at the Johns Hopkins University School of Medicine, where he studied cardiopulmonary physiology, in 2002. Over the next seven years, Dr. Campen worked at the Lovelace Respiratory Research Institute in Albuquerque, New Mexico as an independent scientist. In 2007, he also took on the role of Director of Cardiovascular and Pulmonary Physiology, Toxicology Division, at LRRI. In 2009, Dr. Campen moved across town, accepting a position as Associate Professor in the Department of Pharmaceutical Sciences at the University of New Mexico. He is a full member of the Society of Toxicology and is active in the Mountain West Regional Chapter and Inhalation and Respiratory Specialty Section, in addition to serving as President and founding member of the Cardiovascular Toxicology Specialty Section.

Cardiovascular Specialty Section

Kevin Dreher, Ph.D., Vice President

Dr. Kevin Dreher received his B.S. in Chemistry from Villanova University in 1974 and his M.S. and Ph.D. degrees in Biochemistry from the Pennsylvania State University in 1977 and 1980, respectively. He was a postdoctoral staff fellow at the NIAID/NIH from 1980–1983 and Assistant Professor, Dept. of Biochemistry, West Virginia University School of Medicine from 1983–1987. Dr. Dreher is a senior investigator at the National Health and Environmental Effects Research Laboratory (NHEERL), U.S. EPA, Science Lead for NHEERL’s engineered nanoparticle health effects research program and Adjunct Professor at the North Carolina State University. Dr. Dreher has received numerous U.S. EPA Science and Technology Awards including the Agency’s Gold and Silver medals for his research. He has served, and continues to serve, on several NIEHS/NIH specialty grant peer-reviews, journal editorial boards, and national/international Science Advisory Boards. Dr. Dreher has been a member of SOT since 1995, served as Councilor for the Inhalation Specialty Section and is currently Vice President-Elect for the Cardiovascular Toxicology Specialty Section. Dr. Dreher’s research examines the pulmonary and cardiovascular effects of air pollutants and engineered nanomaterials. This research includes identifying host susceptibility/sensitivity factors and the development of predictive alternative testing methods.

Cardiovascular Specialty Section

Daniel J. Conklin, Ph.D., Vice President_Elect

Dr. Conklin is an Associate Professor in the Division of Cardiovascular Medicine at the University of Louisville (Louisville, Kentucky). He received his doctorate in cardiovascular physiology from the University of Notre Dame (1995), and was an NIEHS-Postdoctoral Fellow at the University of Texas Medical Branch (Galveston, Texas; 1996–1998) where he trained with Dr. Paul Boor, M.D. (Department of Pathology) in cardiovascular toxicology. From 1998–2003, Dr. Conklin was an Assistant Professor in the Department of Biological Sciences at the University of Wisconsin-Eau Claire. In 2003, Dr. Conklin was recruited to the University of Louisville to conduct research in “Environmental Cardiology” with Drs. Aruni Bhatnagar, Ph.D. and Sanjay Srivastava, Ph.D. (University of Louisville). He currently is co-chair on an American Heart Association Great Rivers Affiliate Vascular Biology Study Section and is on the editorial board of Toxicology and Applied Pharmacology (2007–Present). Dr. Conklin is author/co-author of over 50 publications including peer-reviewed articles, book chapters and invited reviews. He is an SOT member since 2001 and currently Vice President-Elect of the Cardiovascular Toxicology Specialty Section, and is a member of both the Inhalation and Respiratory and Stem Cells Specialty Sections.

Cardiovascular Specialty Section

Timothy R. Nurkiewicz, Ph.D., Past President

Dr. Nurkiewicz earned his B.S. from Pennsylvania State University and his M.S. from West Virginia University (WVU). After serving in cardio-pulmonary rehabilitation at Allegheny General Hospital, he returned to WVU and earned his Ph.D. in 1999. Dr. Nurkiewicz performed his postdoctoral training at Texas A&M University in the Department of Medical Physiology. While trained as a microvascular physiologist, he has a broad background ranging from bench top in vitro experiments to clinical interactions. Currently, Dr. Nurkiewicz is an associate professor in the Department of Physiology and Pharmacology at the WVU School of Medicine, where he is also a member of the Center for Cardiovascular and Respiratory Sciences. He serves on the Editorial Board of several toxicology journals; is an ad hoc reviewer for numerous journals and study sections; and participates in various committees and consortiums at University, State and National levels. Dr. Nurkiewicz is a founding member of the Cardiovascular Toxicology Specialty Section.

Comparative and Veterinary Specialty Section

Ann F. Hubbs, D.V.M., Ph.D., DACVP, President

Dr. Hubbs received her D.V.M. from Texas A&M University, an M.S. from Purdue, and a Ph.D. from Colorado State University. She received a certificate of residency in veterinary pathology from Colorado State University, is board eligible in laboratory animal medicine, and is a Diplomate of the American College of Veterinary Pathologists. She has been at the National Institute for Occupational Safety and Health within CDC since 1992. Dr. Hubbs is also an adjunct associate professor at West Virginia University. She has authored or co-authored more than a hundred peer-reviewed publications, which have received numerous awards. Dr. Hubbs is a co-recipient of both the 2008 Bullard-Sherwood Award for Research to Practice and the 2008 National Occupational Research Agenda Partnering Award for Worker Health and Safety. She has received multiple awards for using her scientific skills in responding to important events, such as the anthrax events of 2001, Hurricane Katrina, and monkeypox.

Comparative and Veterinary Specialty Section

Louise Abbott, D.V.M., Ph.D., Vice President

Dr. Abbott received her B.A. in Biology from Whitman College, Ph.D. in Zoology from the University of Washington and D.V.M. from Washington State University. She has been a faculty member at Texas A&M University (TAMU) since 1993 and holds the rank of Associate Professor. Dr. Abbott has been a member of the TAMU Faculty of Toxicology since she joined the TAMU faculty. She uses mouse and zebrafish animal models to investigate mechanisms underlying the adverse effects of chronic, low dose methylmercury exposure on brain development and function. She has trained 15 graduate stidemts, with two M.S. students and three Ph.D. students trained through the TAMU Toxicology program, with an emphasis on neurotoxicology. Dr. Abbott currently teaches an undergraduate class in developmental neurotoxicology. She teaches histology and embryology to first year veterinary students and embryology and neuroscience to graduate students. She regularly reviews manuscripts for five toxicology journals and she serves on the editorial board for Toxicology Letters and the advisory board for the Journal of Applied Toxicology.

Comparative and Veterinary Specialty Section

Kathleen L. Gabrielson, D.V.M., Ph.D., Past President

Dr. Gabrielson received her Ph.D. in Toxicology from the Johns Hopkins University Bloomberg School of Public Health, and she joined the department of Molecular and Comparative Pathobiology faculty in 2000. She has joint appointments in Environmental Health Sciences, Pathology, Pathobiology and CAAT. She has a supportive faculty role in the Bloomberg School of Public Health NIEHS center and the School of Medicine small animal imaging research program (SAIRP) for histopathology, in vivo imaging and animal model expertise. She serves on the editorial boards of Toxicologic Pathology and Cardiovascular Toxicology. Dr. Gabrielson has a teaching and clinical role in the MCP Comparative Veterinary Medicine postdoctoral training program. She currently serves as an officer for the American College of Veterinary Pathologists and the Society of Toxicology. She is a member of the SOT Continuing Education and K–12 committees and a proctor on the National Exam Committee of the American College of Veterinary Pathologists. She is the author or co-author of more than 60 peer-reviewed papers.

Dermal Toxicology Specialty Section

Carol Sabourin, Ph.D., President-Elect

Dr. Sabourin is Senior Research Leader in National Security Global Business at Battelle and Chief Scientist for the Biomedical Science and Technology product line. She received her M.S. in Biochemistry from Michigan State University in 1977 and her Ph.D. in Biology from the University of New Mexico in 1991. She has more than 25 years of professional experience in molecular biology, biochemistry, and molecular toxicology, and 11 plus years in biodefense research for both chemical and biological agents. Her research has focused on host immune response and biomarkers for chemical and biological agents. She currently serves as principal investigator for studies to identify immunological correlates of protection for biodefense vaccines. She is on the Editorial Board of the Journal of Biochemical and Molecular Toxicology and an ad hoc review for numerous journals. She is Adjunct Associate Professor in the Department of Pharmacology and Toxicology, School of Medicine at Wright State University where she teaches and has graduate students. She serves on the Materials Technical Advisory Committee for the U.S. Department of Commerce Bureau of Industry and Security. Dr. Sabourin has authored or co-authored more than 60 manuscripts, and numerous abstracts, presentations, and reports. She is currently an officer of the Dermal Toxicology Specialty Section.

Drug Discovery Toxicology Specialty Section

Craig E. Thomas, Ph.D., President

Dr. Thomas is a Sr. Research Advisor in the Department of Investigative Toxicology at Lilly Research Laboratories. He joined Eli Lilly & Co. in 1996, and in 2000, he became the Department Head of Investigative Toxicology and Toxicology Projects at the Lilly Development Centre in Belgium. In 2005, he took over leadership of Lilly’s toxicogenomics efforts. Dr. Thomas became a full member of SOT and the Mechanisms Specialty Section in 1997, and is currently a member of the Drug Discovery Toxicology Specialty Section and the Ohio Valley Regional Chapter. He is a past recipient of the Mechanisms Specialty Section Carl C. Smith Award and has twice served as a judge on the committee. Dr. Thomas serves on the Advisory Council for the Critical Path Institute Predictive Safety Testing Consortium and has authored 45 peer reviewed journal articles and 25 invited review articles. He holds 4 U.S. patents and is the Co-Editor of the book “Oxygen Radicals and the Disease Process.”

Drug Discovery Toxicology Specialty Section

John Wisler, Ph.D., DABT, Vice President

Dr. Wisler received his Ph.D. in Toxicology from the Indiana University School of Medicine in 1988. He was a National Research Council postdoctoral fellow with the US Army Institute of Chemical Defense (Maryland) during 1988–1989. During the last 20 plus years, he has worked for several multinational companies including IRDC (MPI), Procter and Gamble and Allergan. He joined Amgen during 2003 and currently serves as Scientific Director of Toxicology within Amgen's Comparative Biology Safety Science group. His career work has focused primarily on programs ranging from drug discovery to post marketing activities in both biopharmaceuticals and small molecules. He has been a Diplomat of the American Board of Toxicology since 1992 and currently serves as President of the American Board of Toxicology. He has been an active member of the Society of Toxicology (SOT) since 1983 and is currently Vice President of the Drug Discovery Toxicology Specialty Section. He is also Past President of the Southern California Chapter of SOT and past Councilor for the Northern California Chapter of SOT. He is also a member of the American College of Toxicology.

Drug Discovery Toxicology Specialty Section

Yvonne Will, Ph.D., Vice President-Elect

Dr. Will pursued her graduate studies at Oregon State University in the lab of Dr. Donald Reed where she focused on the relationships between glutathione deficiency and cellular and mitochondrial function/dysfunction. During her years at MitoKor, San Diego (2000–2003) she was involved in drug discovery aimed on improving mitochondrial function or preventing mitochondrial dysfunction in obesity, diabetes, and CNS related diseases. From 2003 until 2007, Dr. Will was a group leader in Drug Safety at Pfizer La Jolla, pioneering a screening paradigm for drug induced mitochondrial toxicity, supporting many therapeutic areas. During that time she also held an adjunct faculty position at San Diego State University in the Toxicology program where she conducted lectures, taught laboratory courses and mentored MS students. In the fall of 2007, Dr. Will transferred to Pfizer Groton to lead a group of scientists in the Compound Safety Prediction Group within Medicinal Chemistry. This group is set out to conduct in vitro safety assessment as early as possible within the drug discovery process to reduce late stage attrition. Dr. Will has published a book on drug induced mitochondrial toxicity together with Dr. James Dykens. Dr. Will has given many national and international lectures, conducted workshops and seminars and continues to publish in peer reviewed journals. Dr. Will has been an active member of SOT and has chaired CE courses, plenary sessions and many poster exhibitions. Her Pfizer team has had numerous contributions each year.

Ethical, Legal, and Social Issues Specialty Section

Gary E. Marchant, Ph.D, J.D., Vice President-Elect

Professor Marchant is the Lincoln Professor Emerging Technologies, Law and Ethics at the Sandra Day O’Connor College of Law at Arizona State University (ASU). He is also a Professor of Life Sciences, Executive Director of the ASU Center for Law, Science and Innovation, and Senior Sustainability scientists in the Global institute of Sustainability at ASU. Professor Marchant has a Ph.D. in Genetics from the University of British Columbia, a Masters of Public Policy degree from the Kennedy School of Government, and a JD from Harvard Law School. Prior to joining the ASU faculty in 1999, he was a partner in the Washington, D.C. office of the law firm Kirkland & Ellis where his practice focused on regulatory issues. Professor Marchant teaches and researches in the subject areas of environmental law, risk assessment and risk management, genetics and the law, biotechnology law, food and drug law, legal aspects of nanotechnology, and law, science and technology.

Ethical, Legal, and Social Issues Specialty Section

Phil Wexler, B.S., M.L.S., Past President

Mr. Wexler is a Technical Information Specialist at the National Library of Medicine’s Toxicology and Environmental Health Information Program, where he has been instrumental in developing and enhancing the TOXNET system. He oversees the NLM-SOT project, ToxLearn, spearheaded the development of the World Library of Toxicology, Chemical Safety and Environmental Health, and is a frequent teacher and lecturer on toxicology information systems. He manages the LactMed database on drugs and lactation, as well as NLM’s risk assessment information resources.

Mr. Wexler is Editor-in-Chief of Elsevier’s Information Resources in Toxicology and the Encyclopedia of Toxicology (3rd edition in preparation), and the author of numerous papers. He is editor of the Taylor and Francis monograph, Chemicals, Environment, Health: A Global Management Perspective, scheduled for 2011 publication.

A past Chair of the SOT’s World Wide Web Advisory Committee, Mr. Wexler was also a member of the Education and Communications Work Group of the CDC/ATSDR’s National Conversation on Public Health and Chemical Exposure project. He serves as federal liaison for the Toxicology Education Foundation, is co-founder of the Toxicology History Room, and president of the Toxicology History Association. In 2010, he was awarded SOT’s Public Communications Award.

Food Safety Specialty Section

James C. Griffiths, Ph.D., Vice President

James C. Griffiths, Ph.D. is Vice President of Food, Dietary Supplement, and Excipient Standards at the U.S. Pharmacopeia, in charge of excipient, dietary supplement and food ingredient issues and publications. Prior to joining USP, Dr. Griffiths was the Senior Toxicologist and Director of Toxicology and Business Development in the toxicology consulting firm of the Burdock Group, located in Vero Beach, Florida. Dr. Griffiths has a doctoral degree in Toxicology from Rutgers University and the University of Medicine and Dentistry of New Jersey, and postdoctoral work in physiological chemistry from the Heinrich Heine University in Düsseldorf, Germany. He has over 25 years of regulatory and safety experience, with the U.S. FDA Center for Food Safety and Applied Nutrition, national trade associations (Distilled Spirits Council of the U.S. and the Flavor and Extract Manufacturers Association), and end-use consumer companies with pharmaceutical excipient, food additive, flavor, cosmetic, and personal care product lines (International Specialty Products and Avon Products). He is an adjunct professor with J.S.S. University Medical Campuses in Mysore and Ootacamund, India and on the editorial board of the Journal of Excipients and Food Chemicals. Dr. Griffiths is a Diplomate of the American Board of Toxicology, a Fellow of the Society of Biology, board certified in medical technology, and a member of the Society of Toxicological Pathology, Society of Regulatory Toxicology and Pharmacology, the American College of Toxicology, and the Institute of Food Technologists. Dr. Griffiths has been a member of Society of Toxicology since 1980 and is very active in the Food Safety Specialty Section (FS3), having served as both Secretary-Treasurer (1995–1997) and Councilor (2008–2010).

Immunotoxicology Specialty Section

Rodney Dietert, Ph.D., President

Dr. Dietert is Professor of Immunotoxicology in the Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York. While at Cornell, Dr. Dietert has held the posts of Director of the Institute for Comparative and Environmental Toxicology (ICET), Director of Graduate Studies for the Graduate Field of Immunology, Senior Fellow in the Cornell Center for the Environment and Director of the Cornell Program on Breast Cancer and Environmental Risk Factors (BCERF). Dr. Dietert’s research emphasizing developmental immunotoxicity (DIT), patterns of immune dysfunction-based disease, and safety protection for pregnant women and children has produced more than 300 publications including over 170 research papers appearing in more than 60 scientific journals. Dr. Dietert has served as a consultant on strategies for immune safety testing of chemicals and drugs and immune optimization in children. His work was featured on the January 2009 cover of Chemical Research in Toxicology. Dr. Dietert currently serves on panels for the WHO, the Institute of Medicine and the U.S. EPA. His recent books include: Strategies for Protecting Your Child’s Immune System (World Scientific, as senior author) and Immunotoxicity Testing: Methods and Protocols (Springer, as editor).

Immunotoxicology Specialty Section

Gregory S. Ladics, Ph.D., DABT, Vice President

Dr. Ladics received his B.S. cum laude from the Philadelphia College of Pharmacy and Science in 1987. In 1991, he received his Ph.D. from the Medical College of Virginia/Virginia Commonwealth University. He has been employed by the DuPont Co. for over 18 years, where he is presently a Senior Research Scientist. He has been a member of Society of Toxicology and the Immunotoxicology Specialty Section since 1989. In 1999, Dr. Ladics became a Diplomate of the American Board of Toxicology. He serves on the International Life Sciences Institute’s (ILSI) Technical Committee on Protein Allergenicity (Chair), and the ILSI Immunotoxicology Technical Committee. Dr. Ladics also chairs the Crop Life International Expert Allergy Team. He is a member of the Editorial Boards of the Journal of Immunotoxicology and Toxicology Letters. He has previously served as Councilor and on the Program Committee for the Immunotoxicology Specialty Section and received the Young Investigator Award in 2006 for accomplishments in the field of Immunotoxicology. Dr. Ladics has co-authored over 140 abstract, journal, and book chapter publications in the field of Immunotoxicology and Allergy.

Immunotoxicology Specialty Section

Leigh Ann Burns-Naas, Ph.D., DABT, Past President

Dr. Burns-Naas received her Ph.D. from the Medical College of Virginia, completed an NIH postdoctoral fellowship at the Mayo Clinic, and is certified by the American Board of Toxicology. Her career has focused primarily on the strategic aspects and design of safety programs to support chemical product development and registration, and to support the clinical development and licensure for small molecules and biotherapeutics. Dr. Burns-Naas maintains an active involvement in Immunotoxicology, including journal editorial board/ad hoc reviewer, teaching at local universities, participation in the HESI ITC, and membership on the Pfizer DSRD Immunotoxicology Council and Biotherapeutics and Biotechnology Network. In addition to her responsibilities with the Immunotoxicology Specialty Section, she is a Councilor for the Women in Toxicology Special Interest Group, founding member of the Biotechnology Specialty Section, former member of the Continuing Education Committee, and current member of the Scientific Program Committee. She is also a Past President of the American College of Toxicology.

In Vitro and Alternative Methods Specialty Section

Sharon Meyer, Ph.D., Vice President

Dr. Meyer received her B.S. and M.S. from Iowa State and her Ph.D. from Cornell. She held postdoctoral positions at Harvard Medical School and University North Carolina. She is currently an Associate Professor in the Department of Toxicology, University of Louisiana-Monroe. She has published more than 40 papers on primary hepatocytes and enterocytes, neural and hepatoblastoma cell lines, and bone marrow stem cells. Her research is funded by DoD, and she has authored “Cellular Techniques in Toxicology” for Molecular and Biochemical Toxicology, 4th edition. Dr. Meyer has served as Vice President-Elect and Secretary/Treasurer for IVAM and as President of the South Central Regional Chapter, SOT. She believes an important priority for IVAM is facilitating education of toxicologists at all career stages to enable critical intergration of multiple cellular/molecular responses to chemicals to understand oraganismal adverse responses. Through this service, it is anticipated that IVAM can impact on rational use of reductionist approaches to predict adverse human health effects.

Inhalation and Respiratory Specialty Section

Michael Kleinman, Ph.D., Vice President

Dr. Kleinman received his B.S. and M.S. in Chemistry in 1965 and 1971, respectively. He received his Ph.D. in Environmental Health Sciences from New York University in 1977. He is currently a Professor in the Department of Medicine at the University of California, Irvine, and Co-Director of the Air Pollution Health Effects Laboratory. Dr. Kleinman has published 100+ articles on toxicology of inhaled environmental contaminants. He served on two National Research Council committees on effects of chemical and biological weapons, and he currently chairs the California Air Quality Advisory Committee. He also serves on U.S. EPA Clean Air Scientific Advisory Committee (CASAC) panels. Dr. Kleinman has been a member of the Society of Toxicology’s Southern California Regional Chapter since 2002 and a member of the Inhalation and Respiratory Specialty Section since 2004.

Inhalation and Respiratory Specialty Section

M. Ian Gilmour, Ph.D., Vice President-Elect

Dr. Gilmour is Chief of the Cardiopulmonary and Immunotoxicology Branch of the U.S. EPA’s Office of Research and Development in RTP. He received an Honors degree in Microbiology from the University of Glasgow, and a doctorate in Veterinary Science from the University of Bristol in 1988. After postdoctoral work at John Hopkins University and the University of North Carolina he joined the U.S. EPA in 1998. He holds adjunct faculty positions with the UNC School of Public Health and the Curriculum in Toxicology, and at NC State Veterinary School. He has been a full member of the SOT since 1992, previously served as elected Councilor for the Inhalation and Respiratory Specialty Section (2002–2004), and is currently Vice President-Elect. He has chaired and participated in numerous symposia and workshops at SOT and has published over 80 research articles in the field of pulmonary immunobiology where his research focuses on the interaction between air pollutant exposure and the development of infectious and allergic lung disease.

Inhalation and Respiratory Specialty Section

Vincent Castranova, Ph.D., Past President

Vincent Castranova, Ph.D., is the Chief of the Pathology and Physiology Research Branch in the Health Effects Laboratory Division of the National Institute for Occupational Safety and Health, Morgantown, West Virginia. He holds the grade of a CDC Distinguished Consultant. He received the Shepard Lifetime Scientific Achievement Award from CDC in 2008 and the Stokinger Outstanding Achievement in Industrial Toxicology Award from ACGIH in 2009. He is also an adjunct professor in the Department of Basic Pharmaceutical Sciences at West Virginia University, Morgantown, West Virginia and the Department of Environmental and Occupational Medicine at the University of Pittsburgh.

Dr. Castranova received a B.S. in biology from Mount Saint Mary’s College, Emmitsburgh, Maryland in 1970, graduating magna cum laude. He received a Ph.D. in physiology and biophysics in 1974 from West Virginia University, Morgantown, West Virginia before becoming an NIH fellow and research faculty member in the Department of Physiology at Yale University, New Haven, Connecticut. In 1977, Dr. Castranova received a research staff position at the National Institute for Occupational Safety and Health and an adjunct faculty position at West Virginia University, Morgantown, West Virginia. He has served at these institutions since that time.

Dr. Castranova’s research interests have been concentrated in pulmonary toxicology and occupational lung disease. He has been coordinator of the Nanotoxicology Program in NIOSH since its inception in 2005. He has been a co-editor of four books and has co-authored over 470 manuscripts and book chapters.

Mechanisms Specialty Section

Michael D. Aleo, Ph.D., Vice President

Dr. Aleo completed postdoctoral training as an NIH National Research Service Award Fellow at the University of Georgia after receiving a Ph.D. in Pharmacology and Experimental Therapeutics from The State University of New York at Buffalo.  As a Research Fellow at Pfizer, he investigates biochemical mechanisms of drug-induced toxicity.  Michael has received two Pfizer Achievement Awards and currently co-chairs the Pfizer Hepatic Injury Council.  Michael has served on the editorial board of Toxicology and Applied Pharmacology and In Vitro Toxicology and is a full member of the Society of Toxicology where he is a contributing member to several specialty sections.

Mechanisms Specialty Section

José E. Manautou, Ph.D., DABT, Past President

Dr. José E. Manautou is Associate Professor of Toxicology and the Marlene L. Cohen and Jerome H. Fleisch Scholar in the Department of Pharmaceutical Sciences at the School of Pharmacy of the University of Connecticut. His research emphasizes mechanisms of toxicant action/interaction. His laboratory studies the role of multidrug resistance proteins in the hepatobiliary disposition of toxicants and the changes in expression of transport proteins in response to chemical liver injury. His group also investigates the biochemical and genetic determinants associated with the hepatoprotective actions of peroxisome proliferators and other chemicals that prevent drug liver injury. He has published numerous seminal articles on these research areas in both toxicology and liver-related journals. Dr. Manautou has been an active member of the Society of Toxicology (SOT) since he joined as a student member. In 2003, he was elected Councilor of the SOT and has also served in key committees and task forces for the society. Dr. Manautou was the recipient of the 2006 SOT Achievement Award and the 2008 AstraZeneca Traveling Lectureship Award. Dr. Manautou has served as member of the National Research Council Committee Assessing the Human Health Risks of Trichloroethylene and is currently Associate Editor for the journal Toxicology and Applied Pharmacology. He is also on the editorial board of four other journals. He served as member of the National Institutes of Health Xenobiotic and Nutrient Disposition and Action (XNDA) Study Section and as external reviewer of grants for the European Commission. Dr. Manautou was recently appointed the NIH College of CSR Reviewers and was just nominated to be a member of the NIEHS Board of Scientific Counselors. Dr. Manautou received his B.S. in Pharmacy from the University of Puerto Rico, Ph.D. in Pharmacology and Toxicology from Purdue University and postdoctoral training in biochemical toxicology at the University of Connecticut. He also conducted sabbatical research at the Amsterdam Liver Center of the University of Amsterdam, The Netherlands.

Medical Device Specialty Section

Richard W. Hutchinson, D.V.M., Ph.D., DABT, President

Dr. Richard W. Hutchinson received his B.S. from the University of Puget Sound in 1992. He received both a D.V.M. and a Ph.D. in Veterinary Anatomy from Texas A&M University in 1996 and 1998 respectively. He joined Johnson & Johnson (Ethicon) in 1998, and is currently a Research Fellow in the Preclinical Sciences Department. He is a diplomat of the American Board of Toxicology, and has been a member of the Society of Toxicology since 1999. He is chairman of the International Standards Organization (ISO) Subcommittee on Tissue product safety (ISO TC194/SC1).

Metals Specialty Section

J. Christopher States, Ph.D., President

Dr. States received his B.S (Biochemistry) from State University of New York at Buffalo in 1974 and a Ph.D. (Pathology & Molecular Biology) from Albany Medical College, Union University in 1980. He was a postdoctoral fellow in the Department of Medical Biochemistry at University of Calgary (1980–1984). He is currently Professor, Distinguished University Scholar and Director of Graduate Admissions in Pharmacology & Toxicology, and Deputy Director of Center for Environmental Genetics and Integratives Biology at the University of Louisville School of Medicine. He served on multiple NIH grant review panels including Superfund, MBRS and ALTX-1 and XNDA Study Sections. He joined SOT in 1997 and is a member of Metals (Secretary/Treasurer, 2005–2007; VP-Elect, 2009), Molecular Biology, Reproductive and Developmental, and Cardiovascular Specialty Sections and Ohio Valley Chapter (Councilor, 2006–2010). His research interests include molecular biology and molecular genetics of arsenic toxicology and DNA damage and repair in humans.

Metals Specialty Section

Michael Hughes, Ph.D., DABT, Vice President

Dr. Hughes is a Research Toxicologist at the U.S. Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory in Research Triangle Park, NC. He received his doctorate in Toxicology from the University of Kentucky in 1986 and was a postdoctoral fellow at the National Institute of Environmental Health Sciences from 1986–1990. He has been a Diplomate of the American Board of Toxicology since 1990. In 1995, Dr. Hughes joined the U.S. EPA where his research interests focused on disposition of arsenicals and pesticides. He has served as a member of the Expert Group for Revising Test Guideline 417 (Toxicokinetics), Organization for Economic Cooperation and Development; ILSI Health and Environmental Sciences Institute Technical Committee on Integration of Biomonitoring Exposure Data into the Risk Assessment Process; Project Advisory Committee (Arsenic Effect on Gene Expression) for the American Water Works Association Research Foundation; and as a Temporary Advisor, World Health Organization, Task Group on Arsenic and Arsenic Related Compounds. Dr. Hughes is author/co-author of 63 publications including peer-reviewed articles and/or book chapters. He has been a member of the SOT since 1986 and has served the SOT in the following capacities: Secretary/Treasurer, Vice President-Elect, North Carolina Regional Chapter; Secretary/ Treasurer, Vice President-Elect, Metals Specialty Section; Nominations Committee; Regional Chapter Governance Committee.

Metals Specialty Section

Aaron Barchowsky, Ph.D., Past President

Dr. Barchowsky received his B.S. in Zoology from North Carolina State University in 1978 and a Ph.D. in Pharmacology from Duke University in 1984. He was a postdoctoral fellow in the Toxicology Training Program at Duke from 1985–1988 and held faculty positions in Clinical Pharmacology at Thomas Jefferson Medical School (1988–1991), the Department of Pharmacology and Toxicology at Dartmouth (1991–2003), and joined the Department of Environmental and Occupational Health at the University of Pittsburgh in 2003. He is active in graduate toxicology education and directs the Environmental Health Sciences Ph.D. program. He served on a number of national scientific review panels, including ALTX1, SIEE, XNDA, and VCMB. He also served as a consultant to the U.S. EPA on arsenic in drinking water and the Institute of Medicine on chromium supplements. He has been a Society member since 2001. He is the Past President of the Metals Specialty Section, and is an active member of both the Mechanisms and Cardiovascular Toxicology Specialty Sections. He is President-Elect of the Allegheny-Erie Regional Chapter. He has maintained an NIH-funded research program investigating cellular signaling mechanisms of oxidants and the molecular pathogenesis of metals-induced vascular and pulmonary diseases.

Mixtures Specialty Section

Michael Dourson, Ph.D., DABT, ATS, President

Dr. Dourson is the President of the non-profit group Toxicology Excellence for Risk Assessment (TERA). Prior to TERA, he worked for 15 years for Environmental Protection Agency, holding several leadership roles and winning 4 bronze medals for joint efforts on specific key projects. Dr. Dourson received the SOT 2003 Lehman Award and the International Society of Regulatory Toxicology and Pharmacology’s 2009 International Achievement award. Two of his publications have won paper of the year awards from the SOT’s Risk Assessment Specialty Section (RASS). He has been elected to multiple officer positions including President of the American Board of Toxicology, President of the SOT RASS, Vice President-Elect of the SOT Mixtures Specialty Section, and Secretary of the Society for Risk Analysis. He is a media resource specialist in risk assessment for the SOT, a member of the editorial board of two journals, and vice chair of the NSF International Health Advisory Board.

Mixtures Specialty Section

Kendall Wallace, Ph.D., DABT, ATS, Vice President

Dr. Wallace is Professor of Biochemistry & Molecular Biology, University of Minnesota Medical School and Director, University of Minnesota Toxicology Graduate Program. He is a Diplomate of the American Board of Toxicology (1992), a Fellow of the Academy of Toxicological Sciences (2005), Editor of Toxicology, and President of StrataTox LLC. Dr. Wallace received his Ph.D. in Physiology from Michigan State University (1979) and was a Postdoctoral Fellow at the University of Iowa Toxicology Center (1979–1981). He has served SOT as President (2005–2006), Chair of the Continuing Education Committee (1991–1993), Finance Committee (1994–1997), President of the Northland Regional Chapter (1998–2000), Council Secretary (1999–2002) and Nominating Committee (2009–2011). His professional service includes: President of the Board of Directors, American Board of Toxicology (2001–2002), Vice-Chair and Chair of the Board of Directors for the ILSI Health and Environmental Sciences Institute, Councilor for IUTOX (2003–2004), U.S. EPA FQPA Scientific Advisory Panel member (1999–2001), Chair of the U.S. FDA Expert Working Group on Preclinical Biomarkers of Drug-induced Cardiac Injury, and President of the Mitochondrial Research Society (2003–2005).

Mixtures Specialty Section

David R. Mattie, Ph.D., DABT, Vice President-Elect

Dr. Mattie is a Senior Research Toxicologist in the 711 Human Performance Wing, Air Force Research Laboratory (711 HPW/RHPB), Wright-Patterson AFB, Ohio. Dr. Mattie received his bachelor’s degree in Biology from Quincy College in Quincy, Illinois in 1974; his master's (Biology, 1977) and Ph.D. (Biology, 1983) from the University of Dayton, Dayton, Ohio. He has been certified as a Diplomat of the American Board of Toxicology since 1991. He is the Section Chief for the Nano/Toxicology Section which includes predictive toxicity research. His projects include nanotoxicology, modeling of complex mixtures, alternative and biobased jet fuel toxicity, dioxane, fuel-induced hearing loss and new propellants.

Professional affiliations include membership in the Society of Toxicology (SOT); Sigma Xi; Ohio Valley Society of Toxicology (OVSOT) in which he served as President until May 1, 2009; and is currently Vice-President for the Mixtures Specialty Section of SOT. Dr. Mattie teaches part-time at Sinclair Community College and is an Adjunct Associate Professor in the Department of Biology at the University of Dayton.

Molecular Biology Specialty Section

Russell S. Thomas, Ph.D., President

Dr. Thomas is a senior investigator at The Hamner Institutes for Health Sciences. Dr. Thomas is also the Director of the Center for Genomic Biology and Bioinformatics and Associate Director of the Program in Chemical Safety Sciences at the Hamner Institutes. His laboratory has diverse interests that range from basic research in cancer biology to applied research in chemical risk assessment. Dr. Thomas completed his M.S. in radiation ecology and Ph.D. in Toxicology at Colorado State University. Following his doctoral studies, Dr. Thomas performed postdoctoral research in molecular biology and genomics at the McArdle Cancer Research Laboratory at the University of Wisconsin. Prior to coming to The Hamner, Dr. Thomas worked in the biotech and biopharmaceutical industry.

Molecular Biology Specialty Section

Chris Corton, Ph.D., Vice President

Dr. Corton is presently a Senior Research Biologist in the Systems Biology Branch in NHEERL at U.S. EPA. He received his Ph.D. from the University of Kansas Medical Center in 1985 followed by a postdoctoral fellowship in yeast molecular biology at Duke University. From 1989 to 2002, he was a staff scientist at CIIT. Dr. Corton has been a member of SOT and the Molecular Biology Specialty Section since 1992. He was a member and Chair of the Continuing Education Committee and is past Secretary/Treasurer of the Carcinogenesis Specialty Section. He is the recipient of the 2010 AstraZeneca Traveling Lectureship award. Dr. Corton is active in SOT and has organized and co-chaired many symposia, roundtables, and CE courses. He is presently on the editorial boards of 6 journals including Toxicological Sciences and has been a reviewer and chair on over 30 peer review committees for NIH/NIEHS grants. As Vice President-Elect of the Molecular Biology Specialty Section (MBSS), he hopes to increase the career and educational opportunities for MBSS members, especially students and postdoctoral fellows, by further developing the interactions between MBSS and other specialty section and special interest groups in SOT and related scientific societies.

Molecular Biology Specialty Section

Christopher A. Reilly, Ph.D., Past President

Dr. Reilly is a Research Associate Professor at the University of Utah in the department of Pharmacology and Toxicology. He received his doctorate in Toxicology from Utah State University in 1999 and was a postdoctoral fellow at the University of Utah from 1999–2001. Dr. Reilly’s primary research interests are in pulmonary toxicology, with specific interest in understanding the roles that Cytochrome P450 and Transient Receptor Potential (TRP) cation channels play in xenobiotic disposition and toxicity. He has served as the Mountain West SOT and Molecular Biology Specialty Section VP-Elect, VP, and President as well as on the SOT CE Committee which he chaired in 2011. Dr. Reilly has been a member of the SOT since 1999.

Nanotoxicology Specialty Section

Alison Elder, Ph.D., VIce President-Elect

Dr. Elder received her Ph.D. in Environmental Toxicology from the University of CA, Irvine, where she studied ozone-induced lung inflammation. She went to the University of Rochester for postdoctoral work, thus beginning her focus on ultrafine and nanosized particulate matter toxicology. She is currently an Associate Professor of Toxicology in the Department of Environmental Medicine at the University of Rochester Medical Center.

Dr. Elder’s current research interests include the pulmonary, cardiovascular, and central nervous system inflammatory and oxidative stress-related effects of engineered nanomaterials and ambient air particulate matter and the physicochemical properties of the particles that are linked to response outcomes. Particle biokinetics and the impacts of age and other underlying vulnerabilities on response are also of interest. She has authored numerous research papers in the field, as well as review articles and book chapters. Dr. Elder is active in the Society of Toxicology and the American Thoracic Society and serves on the Threshold Limit Value-Chemical Substances committee of the American Conference of Governmental Industrial Hygienists. She is an editorial board member of four journals, including a position as deputy Editor-in-Chief of Nanotoxicology. Her research is supported by the NIH, DoD, and U.S. EPA.

Nanotoxicology Specialty Section

David B. Warheit, Ph.D., DABT, ATS, Past President

Dr. Warheit is a Research Fellow at DuPont Haskell Global Centers in Newark, Delware. He received his B.A. from the University of Michigan and his Ph.D. from Wayne State University School of Medicine. He was awarded an NIH Postdoctoral Fellowship and a Parker Francis Pulmonary Fellowship, both of which he took to NIEHS to study mechanisms of asbestos-related lung disease. In 1984, he moved to DuPont Haskell Laboratory. He has attained Diplomate status from the Academy of Toxicological Sciences (2000) and the American Board of Toxicology (1988) and served on NIH study sections. He has participated in several working groups, including IARC and the National Academy of Sciences, as well as several journal editorial boards, including current Associate Editor for Inhalation Toxicology and Toxicological Sciences. He is a past president of the Inhalation and Respiratory Specialty Section and a current member of the SOT Program Committee.

Neurotoxicology Specialty Section

Gary W. Miller, Ph.D., President

Dr. Miller is a Professor of Environmental Health and Associate Dean for Research in the Rollins School of Public Health at Emory University. He also holds appointments in the Department of Neurology and the Department of Pharmacology in the School of Medicine. He received his PhD in Pharmacology and Toxicology from the University of Georgia (with Rick Schnellmann) and completed postdoctoral fellowships at Emory University (with Dr. Allan Levey) and Duke University (with Dr. Marc Caron). After four years on the faculty at the University of Texas he moved back to Emory University in 2002. Dr. Miller is Director of the NIH-funded Parkinson’s Disease Collaborative Environmental Research Center, a Project Leader on the Emory Udall Parkinson's Disease Center, Director of Emory’s NIEHS-funded Toxicology Training Grant, and Director of the new Environmental Health Sciences doctoral program. Last year Dr. Miller received the Achievement Award from the Society of Toxicology and the Outstanding Mentor Award from the Emory Graduate Division of Biomedical and Biological Sciences.

Neurotoxicology Specialty Section

Pam Lein, Ph.D., Vice President

Dr. Lein received an M.S. in Environmental Health from East Tennessee State University (1983) and a Ph.D. in Pharmacology and Toxicology from the University of Buffalo School of Medicine (1990). She was a postdoctoral fellow in the Department of Molecular Immunology at Roswell Park Cancer Institute from 1990–1992. In 1993, she joined the faculty of the Biology department at Canisius College, where she developed a successful undergraduate program in neuroscience. In 1999, she joined the Department of Environmental Health Sciences, Division of Toxicological Sciences at the Johns Hopkins Bloomberg School of Public Health and began developing an independent research program in developmental neurotoxicology. In 2003, Dr. Lein was recruited to the Center for Research on Occupational and Environmental Toxicology (CROET) at Oregon Health & Science University. In 2008, she became an Associate Professor in Neurotoxicology with tenure in the Department of Molecular Biosciences, School of Veterinary Medicine at UC Davis. Her teaching responsibilities include veterinary and graduate courses in neurochemistry, developmental neurobiology and neurotoxicology. Her service activities include standing membership in the National Institutes of Health Neurotoxicology and Alcoholism (NAL) and in the National Science Foundation (NSF) Review Panel Integrative Organismal Biology/Developmental Systems Cluster. She serves on the editorial board of Toxicology and Applied Pharmacology, Journal of Toxicology, Neurotoxicology, and Current Neurobiological Research. She has been an SOT member since 2000 and a Councilor in the Neurotoxicology Specialty Section from 2005–2007. Dr. Lein’s research focuses on cellular and molecular mechanisms of neurotoxicity with particular emphasis on mechanisms by which organophosphorus pesticides, polychlorinated biphenyls or inflammatory mediators interfere with neuronal connectivity and contribute to childhood diseases such as autism and asthma.

Neurotoxicology Specialty Section

Anumantha Kanthasamy, Ph.D., Vice President-Elect

Dr. Kanthasamy is a Distinguished Professor and the Eugene and Linda Lloyd Endowed Chair of Neurotoxicology in the Department of Biomedical Sciences in the College of Veterinary Medicine, Iowa State University. He is also the chair of the ISU Interdepartmental Toxicology Graduate Program and the founding director of the Iowa Center for Advanced Neurotoxicology (ICAN). Prior to joining ISU, he was a faculty member in the Department of Neurology, University of California, Irvine, and a researcher at Purdue University, West Lafayette, IN. Currently, Dr. Kanthasamy’s research is focused primarily in the areas of neurotoxicology, metal toxicology and molecular toxicology. His major study emphasis is on cellular and molecular mechanisms associated with environmental neurotoxicant-induced cell death signaling pathways as they relate to the pathogenesis of Parkinson’s disease and Prion diseases. In support of his neurotoxicological research, Dr. Kanthasamy has secured multiple grants from the National Institutes of Health and other funding agencies. He has received the highest level of NIH-RO1 funding in the Iowa State University College of Veterinary Medicine during the last ten years. Also, he has received contracts from many pharmaceutical/biotechnology companies including Merck KGaA and Boehringer Ingelheim Pharma GmbH & Co KG. He is a prolific author with more than 100 published research papers and abstracts, and is a frequent invited lecturer at numerous conferences worldwide. At Iowa State, Dr. Kanthasamy teaches toxicology and pharmacology courses to graduate students and veterinary medical students. He regularly serves on a variety of panels including NIH study section review panels and other grant review committees. He also maintains memberships in many preeminent professional organizations including the Society for Neuroscience, American Society for Pharmacology Experimental Therapeutics, and International Society for Neurochemistry. Dr. Kanthasamy has been an SOT member since 1995 and a Councilor in the Association of Scientists of Indian Origin since 2010. He is the Past President of the Central States Regional Chapter and is currently Vice President-Elect of the Neurotoxicology Specialty Section.

Neurotoxicology Specialty Section

Stephen Lasley, Ph.D., Past President

Dr. Lasley received his Ph.D. from the University of Louisville in 1979, and was a postdoctoral fellow in Environmental Health at the University of Cincinnati College of Medicine from 1979–1982. He joined the Dept. of Cancer Biology and Pharmacology at the University of Illinois College of Medicine in 1986. He is Course Director of the Medical Pharmacology course, chairs the local IACUC, has served on numerous grant review panels for NIH/NIEHS, and is an Associate Editor for NeuroToxicology. An SOT member since 1986, he was Councilor for the Neurotoxicology Specialty Section (2004–2006), and during that time, Chair of the subcommittee to review nominations for the NTSS Distinguished Investigator Award. Dr. Lasley has served as Director of the SOT Placement Service (1996–1997) and Chair of the SOT Animals in Research Committee (2004–2005). His research interests concern the neurotoxicity resulting from chronic exposure to heavy metals and the effects on the processes of neurotransmission underlying synaptic plasticity.

Occupational and Public Health Specialty Section

Michael E. Ottlinger, Ph.D., DABT, Vice President

Dr. Ottlinger has B.S. and M.S. degrees in Physics and a Ph.D. in Biophysics, from the Johns Hopkins University. His doctoral work was on the role of Clostridium difficile toxins in psuedomembraneous colitis and antibiotic-associated diarrhea. He was a postdoctoral fellow in Pathology at Harvard Medical School from 1988 to 1993, working on the role of phosphokinase inhibition in the regulation of cellular proliferation. Later, he was a fellow in Pathology and Laboratory Medicine at the Boston Children’s Hospital Medical Center during which time he completed a study on the use of troponin T to detect doxorubin-associated cardiac toxicity. In 1995 he became Chief of Clinical Chemistry and Toxicology at the Boston Veterans’ Affairs Medical Center. In 1999 he joined the Centers for Disease Control and Prevention’s, National Institute for Occupational Safety and Health, working on a number of topics in occupational toxicology. Most recently (2002) he joined U.S. EPA’s Office of Emergency Management. His current duties include: environmental decontamination of biological agents; toxicology consultation; Nat’l BioWatch consequence management planning; and large scale event decontamination and remediation planning. During Hurricane Katrina he served in the New Orleans Incident Command Post as Environmental Unit Leader. CAPTAIN Ottlinger (Ret) also served in the U.S. Navy, on active duty onboard the USS Whipple (FF-1062), and as a Naval Reserve Officer attached to the Office of Naval Research working on weapons of mass destruction-related problems. He is currently an Adjunct Assistant Professor in Pathology at the University of Cincinnati School of Medicine. He is a Diplomat of the American Board of Toxicology.

Occupational and Public Health Specialty Section

Andrew Maier, Ph.D., CIH, DABT, Vice President-Elect

Dr. Maier has 18 years of professional work experience in the areas of environmental health, industrial hygiene, and toxicology. He is currently the Director for the non-profit organization Toxicology Excellence for Risk Assessment (TERA) where he leads efforts in developing occupational and environmental exposure guidelines. He completed his PhD in toxicology from the University of Cincinnati, where he currently holds a position as an Adjunct Associate Professor. He earned a M.S. in Industrial Health from the University of Michigan and is Board certified in both toxicology and comprehensive industrial hygiene practice. Dr. Maier is active in communicating his findings to the broader scientific community through active participation in professional societies and through publication of his work. Recently his research efforts have focused on methods and approaches for using biological exposure and effect markers to reduce uncertainties in risk assessment and methodologies for deriving occupational exposure limits. He is past-chair of the American Industrial Hygiene Association Workplace Environmental Exposure Levels (WEEL) Committee and is also currently serving as a Toxicology Fellow with the National Institute for Occupational Safety and Health.

Ocular Toxicology Specialty Section

JoAnn Schuh, D.V.M., Ph.D., DACVP, DABT, President

Dr. Schuh is the principal in a consultancy in preclinical/nonclinical research and development, which she founded in 2000. This consultancy focuses on toxicology program development for biologics, pharmaceuticals and medical devices, and expert reviews and toxicologic pathology of the immune system and special senses (eye and ear). Dr. Schuh received her D.V.M. and Ph.D. from the University of Saskatchewan (1980 and 1994, respectively), completed a M.S. (Veterinary Sciences) at the University of Wisconsin-Madison (1983) and a veterinary pathology residency at Cornell University (1985). She was board certified by the American College of Veterinary Pathologists (ACVP) in 1987 and by the American Board of Toxicology (ABT) in 1995. Dr. Schuh was an Assistant Professor at the University of Saskatchewan (1985-1987), a Research Associate in pathology and experimental toxicology at Warner-Lambert Parke-Davis Pharmaceuticals (1990–1995) and Research Pathologist at Immunex, Corp. (1995–2000). She has served on the program development committee of the Toxicology and Exploratory Pathology SS and is also a member of the Immunotoxicology and Medical Device SS. Currently, she is co-chair of the Internet Committee of the Society of Toxicologic Pathology (STP) and has also been involved in organizing symposia, workshops and continuing education courses on immunotoxicology, medical devices and ocular toxicology at the SOT and STP meetings. She has been an Associate Editor of review articles for Veterinary Pathology and is currently on the editorial board of Toxicologic Pathology.

Ocular Toxicology Specialty Section

James A. Render, B.S., D.V.M., M.S., Ph.D., Diplomate ACVP, Vice President

Dr. Render is a veterinary pathologist currently at NAMSA, a CRO that specializes in the safety testing of medical devices. He received his doctor of veterinary medicine degree from Michigan State University (MSU) in 1979 and doctorate in veterinary pathology from Purdue University in 1984. In 1985, he became certified as a veterinary pathologist through the American College of Veterinary Pathologists (ACVP). Since 1980, Dr. Render's special area of study has been ocular pathology, including diagnostic and academic ocular pathology (1980 to 2000) and toxicologic ocular pathology (2000 to present). Jim was on the faculty at MSU (1986 to 2000) and left as a Professor. In 2000, he accepted a pathologist position at Pfizer and left in 2010 as a Research Fellow. He is an author/co-author of over 80 publications that include peer-reviewed articles and book chapters. Approximately half of the publications pertain to ocular pathology. During Dr. Render’s career, he has been involved in the activities of the ACVP and has been an invited speaker, consultant and manuscript reviewer on topics pertaining to ocular pathology. He has been a member of SOT since 2009 and is the current Vice President of the Ocular Toxicology Specialty Section.

Regulatory and Safety Evaluation Specialty Section

Timothy Pastoor, Ph.D., DABT, President

Dr. Pastoor obtained his Ph.D. in toxicology from the University of Michigan, is certified by the American Board of Toxicology (DABT-1985), and is a long-standing member of the Society of Toxicology. Dr. Pastoor has over 30 years of international experience in fundamental toxicity testing, mode of action research, and human health risk assessment. He serves on SOT’s Communication Committee, and is a board member of the Toxicology Forum and the Health and Environmental Sciences Institute (HESI).

Dr. Pastoor started his career at Dupont’s Haskell laboratory in 1981 and was Manager of Toxicology at ICI/Zeneca from 1987 to 1998.  Since 1998 he has been with Syngenta, LLC as Head of Human Safety and more recently as Principal Scientist. In these roles he has conducted toxicological research and managed toxicologists and risk assessment experts who use safety, health, and environmental studies with estimated levels of exposure to assess risk to humans and the environment. In his current role as Principal Scientist for Syngenta Crop Protection, Dr. Pastoor oversees toxicological research projects and product development and is a frequent speaker on toxicology and risk assessment subjects.

Regulatory and Safety Evaluation Specialty Section

Daland R. Juberg, Ph.D., Vice President-Elect

Dr. Juberg is a toxicologist and North American leader of the Human Health Assessment Group within Dow AgroSciences (Indianapolis, IN). He received his doctorate in Toxicology from the University of Michigan in 1992 and a M.S. in Environmental Health Sciences (University of Michigan) in 1987. Professional experience includes work as a consultant with the International Center for Toxicology and Medicine; and corporate applied and regulatory toxicology work for Eastman Kodak. He has worked at regional, national and international levels on matters involving health risk and regulatory decision-making. He is involved in several ILSI Task Forces including chair of the Biotech Harmonization TF and has maintained an eager interest in scientific outreach. Dr. Juberg has been a member of the Society of Toxicology since 1990 and has served the SOT in the following capacities: Regulatory Affairs and Legislative Assistance Committee (Chair), Communications Committee (Chair), and Congressional Task Force (Chair). He is presently chairing the TSCA Task Force recently formed by the SOT Council. Dr. Juberg is Vice President-Elect of the Regulatory and Safety Evaluation Specialty Section within SOT and is engaged in several Congressional efforts aimed at highlighting the importance of scientific information in legislation and regulation surrounding public health.

Regulatory and Safety Evaluation Specialty Section

Brian Short, D.V.M., Ph.D., DACVP, Past President

Brian received his D.V.M. from UC Davis (1981), completed his veterinary pathology residency at UF, Gainesville (1984) and was board certified by ACVP in 1985. He was a postdoctoral trainee at CIIT, RTP, NC and received his Ph.D. in Experimental Pathology from UNC, Chapel Hill, NC (1988) with research in alpha 2u-globulin nephrotoxicity and carcinogenesis. Brian was Senior Pathologist at SB Pharmaceuticals from 1988-1998. Brian is at Allergan, Irvine, California, currently serving as Sr Director of Pathology and served as Sr Director of Toxicology from 1998 to 2005. He has served as President of the Toxicologic and Pathology SS and as Councilor for the Carcinogenesis SS. During his leadership in these specialty sections he organized continuing education courses and symposia related to drug safety evaluation (Cardiac, Immunotoxicity, and Carcinogenesis) and has also been involved in organizing symposia on ocular drug safety at ACT and STP meetings. He is a member of the Scientific and Regulatory Policy Committee of STP and BioSafe.

Reproductive and Developmental Toxicology Specialty Section

Barry McIntyre, Ph.D., DABT, Vice President

Dr. McIntyre earned his Ph.D. from Washington State University in 1997 in Pharmacology/Toxicology. He was a National Institute of Environmental Health Sciences National Research Service Award Postdoctoral Fellow at the Chemical Industry Institute of Toxicology (CIIT) from 1998 till 2001. In 2001, he joined the Reproductive and Developmental Toxicology group at the Schering-Plough Research Institute as a reproductive toxicologist. He was accorded increasing levels of responsibilities, ultimately managing the US reproductive and developmental toxicology group. While at Schering-Plough he also represented Drug Safety on drug development teams where he designed, coordinated, and implemented non-clinical drug safety programs to support the clinical development of novel therapeutics. In January 2010, he left the pharmaceutical industry and joined the Toxicology Branch of the National Toxicology Program as a staff toxicologist. Dr. McIntyre has served as an ad hoc member for NIEHS Program Project Grants, NIEHS Special Emphasis Panel of the NTP Reproductive and Developmental Toxicology Board of Scientific Councilors, and the NTP-CERHR Bisphenol A Expert Panel. He has been a member of the SOT since 1992, served as a councilor in the Reproductive and Developmental Toxicology Specialty Section and has been active in the specialty section. He is also a past member of the Middle Atlantic Reproduction and Teratology Association (Councilor).

Reproductive and Developmental Toxicology Specialty Section

Jodi A. Flaws, Ph.D., Vice President-Elect

Dr. Flaws is a Professor in Comparative Biosciences at the University of Illinois-Urbana/Champaign. She received a B.S. (1986) in Biology from St. Xavier University, a M.S. (1990) in Biology from Loyola University of Chicago, and a Ph.D. in Physiology (1994) from the University of Arizona. During her M.S. research, she examined gonadotrope regulation with Dr. Diane Suter as her M.S. advisor. During her Ph.D. research, she examined the effects of an industrial chemical, 4-vinylcyclohexene diepoxide, on the mammalian ovary with Dr. Patricia Hoyer as her Ph.D. advisor. Following completion of the Ph.D. degree, Dr. Flaws performed post-doctoral research on genes and environmental chemicals that regulate female reproductive function in the laboratories of Dr. Jonathan Tilly at Johns Hopkins University and Dr. Anne Hirshfield at the University of Maryland. Following post-doctoral training, she accepted an Assistant Professor position at the University of Maryland (1997) and subsequently was promoted to Associate Professor (2001). In 2006, Dr. Flaws accepted a position as Professor of Comparative Biosciences at the University of Illinois-Urbana/Champaign. 

Dr. Flaws’ research program is mainly focused on determining the mechanisms by which environmental chemicals such as pesticides and plasticizers affect the development and function of the ovary. Her research is funded by grants from the NIH and private foundations. She has published over 130 peer-reviewed papers that have involved extensive participation and authorship by 16 graduate students, 6 post-doctoral fellows, and 10 undergraduate students. She is the recipient of the Department of Epidemiology and Preventive Medicine, University of Maryland Student Mentoring Award (2003), the Patricia Sokolove Outstanding Mentor Award (2006), the Dr. Gordon and Mrs. Helen Kruger Research Excellence Award (2008), the Pfizer Animal Health Award for Research Excellence (2009), and the University Scholar Award (2009–2012). She has served as a Reproductive and Developmental Specialty Section Councilor, an Associate Editor for Toxicology and Applied Pharmacology, and on numerous NIH study sections which review reproductive toxicology grant applications.

Reproductive and Developmental Toxicology Specialty Section

Alan M. Hoberman, Ph.D., DABT, Fellow ATS, Past President

Dr. Hoberman was trained in anatomy and embryology at the University of Virginia and in toxicology at the University of Arkansas and the National Center for Toxicological Research. He worked in the field of toxicology for over 34 years and specialized in reproductive and developmental toxicology for over 31 years. As a Diplomate of the American Board of Toxicology (1988), Dr. Hoberman has over 70 publications and 188 presentations of abstracts and lectures in the fields of reproductive and developmental toxicology, neurotoxicology, inhalation toxicology, photobiology and regulatory toxicology. His current research interests include the development of the immune response and the assessment of compounds in young animals. Dr. Hoberman’s level of expertise in all aspects of preclinical toxicology and chemical safety testing has proven invaluable in the overall approval process to bring new entities to market.

Risk Assessment Specialty Section

Robinan Gentry, Ph.D., DABT, President

Dr. Gentry is currently a Principal Consultant at ENVIRON International Corporation with over 20 years of experience in toxicology and quantitative risk assessment. She received her Ph.D. in toxicology in 2008 from Utrecht University and her M.S. (1992) and B.S. (1987) degrees in toxicology from the University of Louisiana in Monroe. Over her career, she has been a principal investigator or contributing author for numerous risk assessments for both government and industry. The purpose of most of these assessments has been to incorporate innovative quantitative approaches in the determination of acceptable levels of exposure of humans to chemicals in the environment, in pharmaceuticals, and in consumer products. She has over 30 publications in the area of risk assessment, as well as the development of PBPK models and their application into both the cancer and noncancer risk assessment process. She has also been involved in projects using these types of models to investigate human variability by age and gender and the potential impact of this variation on risk assessment. Her recent research interests include projects that are aimed at understanding the mode of action of adverse effects in animals and the implications to human health. She has been a member of SOT since 2002.

Stem Cells Specialty Section

Thomas A. Gasiewicz, Ph.D., Vice President-Elect

Dr. Gasiewicz received his B.S. in Chemistry from Canisius College, and Ph.D. in Toxicology from the University of Rochester. He also performed postdoctoral work at Vanderbilt University. He is currently Professor and Chair of the Department of Environmental Medicine at the University of Rochester Medical Center. He is also Director of the NIEHS Core Center of Excellence at the University of Rochester. He has authored or co-authored over 150 journal articles and book chapters on environmental health-related issues. Most of these have been focused on the molecular and cell biology of receptor-mediated toxicity, and in particular on hematopoietic stem cells. He has served on numerous NIH Study Sections, Scientific Advisory Boards, Editorial Boards, and as Associate Editor for Toxicology and Applied Pharmacology. He is presently serving on the National Advisory Council for NIEHS. He has been a member of SOT since 1977.

Toxicologic and Exploratory Pathology Specialty Section

Doug Wolf, D.V.M., Ph.D., President

Dr. Wolf received his D.V.M. from the University of Missouri in 1981. After 6 years in clinical practice, he completed his pathology residency and Ph.D. in Veterinary Pathology at Purdue University in 1991. Dr. Wolf was a staff scientist for 6 years at the Chemical Industry Institute of Toxicology (CIIT), studying chemical carcinogenesis. From 1997–2007, he was a principal investigator at the National Health and Environmental Effects Research Laboratory (NHEERL) of the U.S. EPA, where he continued his work in carcinogenesis and molecular pathology. Currently, he is an Assistant Laboratory Director for NHEERL. Dr. Wolf has authored or coauthored over 125 journal articles, book chapters, and technical reports and has presented his work at numerous scientific meetings. He is an adjunct faculty member at North Carolina State University; University of North Carolina; and the Virginia Polytechnic Institute. Dr. Wolf was elected a Fellow of the International Academy of Toxicologic Pathologists in 2004 and a Fellow of the Academy of Toxicological Sciences in 2007.

Toxicologic and Exploratory Pathology Specialty Section

Norman J. Barlow, D.V.M., Ph.D., M.B.A., M.L.D., DAVCP, DABT, Vice President

Dr. Barlow received his D.V.M. from Michigan State University in 1996, completed a residency in anatomic pathology at North Carolina State University (NCSU) in 1998, and attained American College of Veterinary Pathology certification in 1999. He earned his Ph.D. in Comparative Biomedical Sciences from NCSU and the CIIT Centers for Health Research in 2003. Dr. Barlow’s doctoral research focused on the morphogenesis of phthalate-induced malformations in the developing male reproductive tract. In 2007, he attained certification by the American Board of Toxicology, and recently completed a Masters of Business Administration and a Masters of Leadership Development at Pennsylvania State University. In 2003, Dr. Barlow joined Aventis Pharmaceuticals as a veterinary pathologist and has had the opportunity to work at various sites including Bridgewater, NJ, Alfortville, France, and Malvern, PA. He was the Acting Head of Pathology in the U.S. from 2008 to 2009 and is currently the U.S. Head of Preclinical Safety for sanofi-aventis. Dr. Barlow has been a member of the SOT since 1999, served as a Councilor for TEPSS from 2008–2010, and has been active on the selection committee for the Roger O. McClellan Student Award.

Toxicologic and Exploratory Pathology Specialty Section

Dennis J. Meyer, D.V.M., DACVIM, DACVP, Vice President-Elect

Dr. Meyer received his D.V.M. from the University of Minnesota in 1972 followed by internship and residency programs in internal medicine at the University of California-Davis. He attained certification in the American College of Veterinary Pathologists (Clinical Pathology) and the American College of Veterinary Internal Medicine (Internal Medicine) in 1979 and 1985, respectively. In 1976, Denny joined the faculty of the University of Florida-College of Veterinary Medicine where he participated in providing primary patient care, conducted clinical research in the diagnosis and management of liver disease, served as Service Chief of Companion Animal Medicine and Service Chief of Clinical Pathology, taught veterinary students and mentored residents in medicine and clinical pathology. After 18 years in academia, Denny joined SmithKline Beecham as Director, Clinical Pathology and Safety Pharmacology followed by positions in small pharmaceutical companies in which he contributed the successful submission of INDs and NDAs. He joined Charles River in Reno, NV in 2003 as principal clinical pathologist and Executive Director, Safety Assessment followed by appointment to Executive Director, Navigator Services; a scientific and regulatory consulting group. He has served as Associate Editor for the Journal of the American College of Veterinary Internal Medicine and on the Editorial Board for the Veterinary Pathology journal and is co-author of two textbooks.

Toxicologic and Exploratory Pathology Specialty Section

Glenn H. Cantor, D.V.M., Ph.D., DACVP, Past President

Dr. Cantor received his A.B. from Cornell University and D.V.M. from Michigan State University. After 5 years in private veterinary practice, he did a residency in anatomic pathology at University of Florida, attained American College of Veterinary Pathology certification in Anatomic Pathology, and received his Ph.D. from the Department of Veterinary Microbiology & Pathology at Washington State University. In 1994, he joined the faculty of the Department of Veterinary Microbiology & Pathology, Washington State University, where he was first an Assistant Professor and then Associate Professor with tenure. His research was on the molecular pathogenesis of bovine leukemia virus infection and its role in altering host B-lymphocyte signal transduction. He also served as a senior diagnostic pathologist in the Washington Animal Disease Diagnostic Laboratory, where he taught residents and veterinary students. In 2002, Dr. Cantor joined the Investigative Pathology unit at Pharmacia Corp., Kalamazoo, Michigan where he coordinated the genetically engineered mouse phenotyping program and did research on metabonomics. In 2003, Dr. Cantor joined the Discovery Toxicology group at Bristol-Myers Squibb Co., Princeton, New Jersey, and is presently a Veterinary Pathology Fellow. He leads the efforts of the metabolism, pharmacokinetics, pharmaceutics, analytic chemistry, biotranformation, and discovery toxicology groups for several drug discovery projects, and serves as toxicology representative and pathologist on a number of other drug projects, mainly in the areas of oncology and cardiovascular disease. He served as associate editor for Veterinary Pathology (2004–2007). He has been a member of the SOT since 2002, served as a Councilor in the Toxicologic and Exploratory Pathology Specialty Section (TEPSS) from 2005 to 2007, and was President of TEPSS (2010–2011).